Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform, marking its entry into the consumer health sector [1] Group 1: Product Development - The two active ingredients developed are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the United States [1] - The combined formulation product Groland has also received FDA registration, indicating regulatory approval for market entry [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including several million dollars in upfront payments and milestone payments [1] - This partnership aims to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, utilizing Ailux's proprietary platform and AI antibody research capabilities [1] - This collaboration follows a previous $250 million agreement between Jingtai Technology and Eli Lilly for AI small molecule drug development [1]
晶泰控股高开近4% 晶泰AI平台成功开发生发“双子星”新分子 获得关键国际认证